Aug 20, 2026 · 10 min
Debt hits $40 trillion as war probes and cancer vaccine advance
$40,047,425,768,420 in U.S. Debt, and an Experimental Vaccine for Skin Cancer
The episode connects an escalating fiscal burden with accountability questions in Gaza and cautious hope for preventing melanoma recurrence.
- 1U.S. borrowing has crossed $40 trillion, while interest costs and failed bipartisan efforts expose the limits of fiscal restraint.
- 2Israeli investigations into alleged wartime killings could trigger criminal cases, even as deadly strikes reportedly continue during the ceasefire.
- 3Early results for an experimental Merck-Moderna mRNA vaccine suggest longer melanoma remission, but its durability remains unknown.
Don't miss
Early trial results suggest a Merck-Moderna mRNA vaccine could help high-risk melanoma patients live longer without their cancer returning.
The brief
The U.S. national debt has surpassed $40 trillion, with rising interest payments and repeated failures by presidents of both parties to reverse the borrowing trend.
Cost-cutting efforts associated with the Trump administration, including Project Doge and tariff strategies, have not solved the underlying fiscal problem.
Isabel Kershner explains how Israeli military investigations into two Gaza incidents could lead to criminal cases, while other cases were dismissed and strikes continued during the ceasefire.
Merck and Moderna report promising early results from an experimental mRNA vaccine for high-risk melanoma, though researchers do not yet know how long its benefit will last.
The episode leaves three unresolved questions: whether debt can be contained, whether investigations produce accountability, and whether early cancer-vaccine gains endure.
Featuring
Isabel Kershner
Donald John Trump
IsraelListen to the full episode and explore every guest, topic, and moment on PodLume.